{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-126220","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.139256+00:00","generated_at":"2026-05-15T08:48:46.639749+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcadia Biosciences reports FY2025 net loss of $2.3M; Zola revenues up 17% YoY; business combination terminated","bullets":["Q4 2025 revenue $901K (-26% YoY); full-year revenue $4.86M (-4%). Net loss per share $1.71 vs $5.17 in 2024.","Zola coconut water sales rose 17% to $701K in 2025; SG&A reduced 27% YoY.","Roosevelt Resources terminated proposed business combination; Arcadia exercises preferred options for $2.1M gross proceeds.","Cash and short-term investments totaled $4.56M at Dec 31, 2025, down from $4.24M cash alone a year earlier.","Net cash used in operations improved 49% to $4.74M in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-126220","json":"https://secwatch.observer/filing/0001193125-26-126220.json","markdown":"https://secwatch.observer/filing/0001193125-26-126220.md","text":"https://secwatch.observer/filing/0001193125-26-126220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526126220/0001193125-26-126220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526126220/rkda-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:48:46.639749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c49afc7f389992925378457d12d8963428b98713","claim":"Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.","evidence_excerpt":"On March 26, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1469443/000119312526126220/0001193125-26-126220-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}